Review: four years of cat-and-mouse chemistry as manufacturers evade China's synthetic cannabinoid ban

Ban-evading strategies included: alternative core structures (oxoindolins, oxopyridone, benzoate), linker replacement (acetamide instead of carboxamide), positional switching on conventional cores, adding or removing substituents (bromination, tail-less compounds), and a do-it-yourself synthesis approach where users convert legal tail-less precursors into banned potent SCRAs.

The review compiled and analyzed all synthetic cannabinoid receptor agonists that emerged between mid-2021 and mid-2025 in response to China's generic ban. The authors categorized ban-evading strategies, discussed detection and metabolic profiling challenges, and presented first-published pharmacological data for some uncharacterized compounds.

China's 2021 ban was one of the most sweeping generic drug scheduling efforts ever attempted. This review documents how four years of manufacturer innovation have already undermined it, creating a flood of novel compounds with unknown potency, toxicity, and metabolic profiles that challenge both forensic detection and emergency medicine.

The DIY synthesis approach is particularly alarming: if users can easily convert legal precursors into potent banned SCRAs, the entire concept of precursor scheduling may need rethinking. This cat-and-mouse dynamic between regulators and manufacturers shows no signs of stabilizing, and each new compound carries unknown risks.

The review focuses on compounds detected in forensic and analytical reports, which may not capture all novel SCRAs in circulation. Pharmacological characterization is incomplete for many compounds. The review does not quantify health outcomes or prevalence of use for individual compounds.